Methylation of 10 miRNA genes in clear cell renal cell carcinoma and their diagnostic value

Introduction. Clear cell renal cell carcinoma (ccRCC) is characterized by the high (30–40 % of cases) frequency of lethal outcomes which at metastasis reaches 90 %. Lack of efficient diagnostics at early stages of a disease indicates the need of searching on new ccRCC markers.

Objective: for definition of methylation role of some tumor suppressor microRNA (miRNA) genes in ccRCC pathogenesis and progression and marker identification for ccRCC diagnostics and metastasis predictions.

Materials and methods. The alterations of methylation status of 10 miRNA genes were determined by methylation specific polymerase chain reaction in tumor DNA samples and matched histologically unchanged tissues from 70 patients with ccRCC, as well as in DNA samples of kidney tissues from 19 post-mortal individuals without cancer history. Methylation of MIR MIR-107, -130b and -148a genes in ccRCC was studied for the first time.

Results. It was shown that 8 miRNA genes (MIR-9-1/3, -34b/c, -124a-1/2/3, -129-2, -130b) were methylated in ccRCC tumors with significantly higher frequency than in the matched histologically unchanged kidney tissues. It was established the association of methylation of 4 miRNA genes (MIR-107, -124a-3, -129-2, -130b) with ccRCC progression (stage, tumor size, differentiation grade), including metastasis in the lymph nodes or distant organs, revealed for MIR-107 and -129-2. The association of MIR-107 and -130b methylation with progression of ccRCC is shown for the first time. Potential marker systems are made for ccRCC diagnostics using tumor biopsy; according to the ROC analysis, systems from 4 and 5 genes (MIR-9-1, -4b/c, -124a-3, -129-2/with addition of MIR-130b) are characterized by high clinical sensitivity of 90 % and specificity of 94 % (area under ROC curve 0.93 and 0.94). 

Conclusion. The received results will form the basis of noninvasive ccRCC diagnostics further development. To conclude, it is shown the association of methylation of 9 miRNA genes with ccRCC pathogenesis and progression and its potential diagnostic value.

1. Vasudev N. S., Selby P. J., Banks R. E. Renal cancer biomarkers: the promise of personalized care. BMC Med 2012;10:112. DOI: 10.1186/1741-7015-10-112. PMID: 23016578.

2. Cairns P. Renal cell carcinoma. Cancer Biomark 2011;9(1–6):461–73. DOI: 10.3233/CBM- 2011–0176. PMID: 22112490.

3. Rydzanicz M., Wrzesinski T., Bluyssen H. A., Wesoly J. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett 2013;341(2):111–26. DOI: 10.1016/j.canlet.2013.08.006. PMID: 23933176.

4. Randall J. M., Millard F., Kurzrock R. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109–24. DOI: 10.1007/s10555-014-9533-1. PMID: 25365943.

5. Каприн А. Д., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2016. 236 с. [Kaprin A. D., Starinskiy V. V., Petrova G. V. State of oncological care in Russia in 2015. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2016. 236 p. (In Russ.)].

6. Jones P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13(7):484–92. DOI: 10.1038/nrg3230. PMID: 22641018.

7. Vrba L., Muñoz-Rodríguez J. L., Stampfer M. R., Futscher B. W. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One 2013;8(1):e54398. DOI: 10.1371/journal.pone.0054398. PMID: 23342147.

8. Kunej T., Godnic I., Ferdin J. et al. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res 2011;717(1–2):77–84. DOI: 10.1016/j.mrfmmm.2011.03.008. PMID: 21420983.

9. Piletič K., Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol 2016;90(10):2405–19. DOI: 10.1007/s00204-016-1815-7. PMID: 27557899.

10. Baylin S. B., Jones P. A. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 2016;8(9):a019505. DOI: 10.1101/cshperspect.a019505. PMID: 27194046.

11. Рыков С. В., Ходырев Д. С., Пронина И. В. и др. Новые гены микроРНК, подверженные метилированию в опухолях легкого. Генетика 2013;49(7):896–901. [Rykov S. V., Khodyrev D. S., Pronina I. V. et al. Novel miRNA genes methylated in lung tumors. Genetika = Genetics 2013;49(7):896–901. (In Russ.)]. DOI: 10.7868/S0016675813070114.

12. Логинов В. И., Бурденный А. М., Пронина И. В. и др. Идентификация новых генов микроРНК, гиперметилированных при раке молочной железы. Молекулярная биология 2016;50(5): 797–802. [Loginov V. I., Burdennyy A. M., Pronina I. V. et al. Novel miRNA genes hypermethylated in breast cancer. Molekulyarnaya biologiya = Molecular Biology 2016;50(5):797–802. (In Russ.)]. DOI: 10.7868/S0026898416050104.

13. Pronina I. V., Loginov V. I., Burdennyy A. M. et al. DNA methylation contributes to deregulation of 12 cancerassociated microRNAs and breast cancer progression. Gene 2017;604:1–8. DOI: 10.1016/j.gene.2016.12.018. PMID: 27998789.

14. Логинов В. И., Рыков С. В., Фридман М. В., Брага Э. А. Метилирование генов микроРНК и онкогенез. Биохимия 2015;80(2):184–203. [Loginov V. I., Rykov S. V., Fridman M. V., Braga E. A. Methylation of miRNA genes and oncogenesis. Biokhimiya = Biochemistry 2015;80(2):184–203. (In Russ.)]. DOI: 10.1134/S0006297915020029.

15. Береснева Е. В., Рыков С. В., Ходырев Д. С. и др. Профиль метилирования группы генов микроРНК при светлоклеточном почечно-клеточном раке; связь с прогрессией рака. Генетика 2013;49(3): 366–75. [Beresneva E. V., Rykov S. V., Khodyrev D. S. et al. Methylation profile of group of miRNA genes in clear cell renal cell carcinoma; involvement in cancer progression. Genetika = Genetics 2013;49(3):366–75. (In Russ.)]. DOI: 10.1134/S1022795413030034. PMID: 23755536.

16. Береснева Е. В., Логинов В. И., Ходырев Д. С. и др. Гиперметилированные гены микроРНК как потенциальные маркеры светлоклеточного рака почки. Клиническая лабораторная диагностика 2017;62(1):13–8. [Beresneva E. V., Loginov V. I., Khodyrev D. S. et al. The hyper-methylated genes microRNA as potential markers of clear-cell carcinoma of kidney. Clinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics 2017;62(1):13–8. (In Russ.)]. DOI: 10.18821/0869-2084-2017-62-1-13-18.

17. Sobin L. H., Gospodarowicz M. K., Wittekind Ch. International Union against Cancer. TNM classification of malignant tumours. 7th edn, 2009. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, 2010. Pp. 332. Available at: https://www.ncbi.nlm.nih.gov/nlmcatalog/101511218.

18. Loginov V. I., Dmitriev A. A., Senchenko V. N. et al. Tumor suppressor function of the SEMA3B gene in human lung and renal cancers. PLos One 2015;10(5):e0123369. DOI: 10.1371/journal.pone.0123369. PMID: 25961819.

19. Lee K. H., Lotterman C., Karikari C. et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009;9(3):293–301. DOI: 10.1159/000186051. PMID: 19407485.

20. Yang C., Cai J., Wang Q. et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012;124(2):325–34. DOI: 10.1016/j.ygyno.2011.10.013. PMID: 22005523.

21. Li H. P., Huang H. Y., Lai Y. R. et al. Silencing of miRNA-148a by hyper methylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. Oncotarget 2014;5(17):7610–24. DOI: 10.18632/oncotarget.2282. PMID: 25277193.

22. Long X. R., He Y., Huang C., Li J. Micro-RNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol 2014;44(6):1915–22. DOI: 10.3892/ijo.2014.2373. PMID: 24714841.

23. Sun J., Song Y., Wang Z. et al. Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers. Onco Targets Ther 2014;7:853–63. DOI: 10.2147/OTT.S60888. PMID: 24920927.

24. Cao H., Liu Z., Wang R. et al. miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2. Oncol Rep 2017;37(1):147–54. DOI: 10.3892/or.2016.5257. PMID: 27878305.

25. Kim E. A., Kim T. G., Sung E. G. et al. miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells. Int J Oncol 2017;50(3):984–92. DOI: 10.3892/ijo.2017.3851. PMID: 28098870.

26. Redova M., Poprach A., Nekvindova J. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012;10:55. DOI: 10.1186/1479-5876-10-55. PMID: 22440013.

27. Wang C., Hu J., Lu M. et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep 2015;5:7610. DOI: 10.1038/srep07610. PMID: 25556603.

28. Yadav S., Khandelwal M., Seth A. et al. Serum microRNA expression profiling: potential diagnostic implications of a panel of serum microRNAs for clear cell renal cell cancer. Urology 2017;104:64–9. DOI: 10.1016/j.urology.2017.03.013. PMID: 28336290.

29. Marconi L., Dabestani S., Lam T. B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660–73. DOI: 10.1016/j.eururo.2016.04.027. PMID: 27157997.